News

January 28, 2021January 28, 2021

FDA Clears Way for Clinical Trial of VOR33 Stem Cell Therapy

News

Vor Biopharma has been cleared in the U.S. to begin clinical trial testing of its investigational cell therapy, VOR33, for acute myeloid leukemia (AML). The U.S. Food and Drug ... Read more

January 21, 2021January 21, 2021

Potentially Less Toxic Chemo for AML Named Orphan Drug in Europe

News

Aspacytarabine (BST-236), a possibly less toxic form of chemotherapy being developed by Biosight for people with acute myeloid leukemia (AML), has been designated an orphan medicinal product by the European ... Read more

January 18, 2021January 18, 2021

Iomab-B Shows Promise as Transplant Conditioning Regimen

News

Iomab-B shows promise as a conditioning regimen for bone marrow transplant in patients older than 55 with active relapsed or refractory acute myeloid leukemia (AML), according to early data ... Read more

January 14, 2021January 14, 2021

Canada Approves Onureg, Oral Chemotherapy for AML Patients in Remission

News

Health Canada has approved Onureg, an oral formulation of the chemotherapy azacitidine, as the first maintenance therapy for adults with acute myeloid leukemia (AML) who have achieved complete remission after intensive induction ... Read more

January 7, 2021January 7, 2021

Ascentage Pharma’s APG-2575 Earns Orphan Drug Designation

News

APG-2575, an investigational Bcl-2 inhibitor being developed by Ascentage Pharma, has received orphan drug designation from the U.S. Food and Drug Administration (FDA) for the treatment of acute myeloid ... Read more

January 4, 2021January 4, 2021

CPI-613 on FDA Fast Track to Treat AML

News

CPI-613 (devimistat) has been granted a fast track designation by the U.S. Food and Drug Administration to treat acute myeloid leukemia (AML), announced its developer, Rafael Pharmaceuticals. The designation ... Read more

December 21, 2020December 21, 2020

NexImmune, City of Hope Partner to Research NEXI-001, New Therapies

News

NexImmune and City of Hope have teamed up on a research initiative aimed at advancing treatment candidate NEXI-001 for acute myeloid leukemia (AML) and identifying new targets for future ... Read more

December 17, 2020December 17, 2020

Venclexta Combos Approved in Canada to Treat Newly Diagnosed AML

News

Health Canada has approved Venclexta (venetoclax) in combination with Vidaza (azacitidine) or low-dose cytarabine to treat newly diagnosed adults, ages 75 and older, with acute myeloid leukemia (AML), who have ... Read more

December 14, 2020December 17, 2020

Potential Cancer Vaccine DCP-001 May Control AML Residual Disease

News

DCP-001, the lead cancer vaccine candidate by DCprime, safely elicited a tumor-specific immune response in patients with acute myeloid leukemia (AML), who still showed signs of residual disease despite ... Read more

December 10, 2020December 10, 2020

OSU Names Leukemia Research Center in Honor of Scientist Clara Bloomfield

News

Clara D. Bloomfield dedicated her career to finding new treatments for patients with acute myeloid leukemia (AML) and related disorders. To continue the work of its longtime faculty member, Ohio ... Read more